VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer

L

Li Liu

Status

Unknown

Conditions

Brain Metastasis
Non Small Cell Lung Cancer

Treatments

Other: bevacizumab, standard chemotherapy and radiation

Study type

Observational

Funder types

Other

Identifiers

NCT01891708
XHZL02

Details and patient eligibility

About

a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer

Full description

non small cell lung cancer (non squamous carcinoma) ECOG 0-1 from 18-75 years old

Enrollment

40 estimated patients

Sex

All

Ages

18 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • non squamous cell non small cell lung cancer
  • with measurable disease
  • ECOG 0-1

Exclusion criteria

- patients received surgery in recent 4 weeks

Trial contacts and locations

1

Loading...

Central trial contact

Li Liu, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems